- Home
- HRMY
as 12-17-2024 4:00pm EST
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | PLYMOUTH MEETING |
| Market Cap: | 1.9B | IPO Year: | 2020 |
| Target Price: | $49.80 | AVG Volume (30 days): | 431.7K |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.11 | EPS Growth: | -14.80 |
| 52 Week Low/High: | $28.14 - $41.61 | Next Earning Date: | 10-29-2024 |
| Revenue: | $681,879,000 | Revenue Growth: | 25.83% |
| Revenue Growth (this year): | 24.79% | Revenue Growth (next year): | 17.98% |
Stock Insider Trading Activity of Harmony Biosciences Holdings Inc. (HRMY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Marshman Fund Trust II | HRMY | 10% Owner | Nov 1 '24 | Sell | $30.30 | 4,600,000 | $139,391,500.00 | 6,651,120 | |
| Valor IV Pharma Holdings, LLC | HRMY | 10% Owner | Nov 1 '24 | Sell | $30.30 | 4,600,000 | $139,391,500.00 | 7,218,033 | |
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Oct 29 '24 | Sell | $40.47 | 21,496 | $870,018.36 | 0 | |
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Oct 3 '24 | Sell | $35.33 | 36,357 | $1,274,546.50 | 0 | |
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Oct 1 '24 | Sell | $40.19 | 400 | $16,076.92 | 0 | |
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Sep 30 '24 | Sell | $40.03 | 35,846 | $1,434,951.23 | 0 | |
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Sep 27 '24 | Sell | $40.05 | 200 | $8,009.00 | 0 |
Latest Harmony Biosciences Holdings Inc. News
HRMY Breaking Stock News: Dive into HRMY Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
HC Wainwright Initiates Harmony Biosciences at Buy With $75 Price Target
Argus Research
8 days ago
HRMY: Lowering target price to $34.00
Argus Research
15 days ago
HRMY: Lowering target price to $36.00
PR Newswire
15 days ago
HARMONY BIOSCIENCES TO PARTICIPATE IN OPPENHEIMER MOVERS IN RARE DISEASE SUMMIT
Argus Research
22 days ago
HRMY: Raising target price to $37.00
PR Newswire
a month ago
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
Argus Research
a month ago
HRMY: Rating increased to a BUY
Argus Research
a month ago
HRMY: Lowering target price to $35.00
Compare HRMY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HRMY Harmony Biosciences Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.